Saltar al contenido
Merck

CARMIL2 Deficiency Presenting as Very Early Onset Inflammatory Bowel Disease.

Inflammatory bowel diseases (2019-05-23)
Thomas Magg, Anna Shcherbina, Duran Arslan, Mukesh M Desai, Sarah Wall, Vanessa Mitsialis, Raffaele Conca, Ekrem Unal, Neslihan Karacabey, Anna Mukhina, Yulia Rodina, Prasad D Taur, David Illig, Benjamin Marquardt, Sebastian Hollizeck, Tim Jeske, Florian Gothe, Tilmann Schober, Meino Rohlfs, Sibylle Koletzko, Eberhard Lurz, Aleixo M Muise, Scott B Snapper, Fabian Hauck, Christoph Klein, Daniel Kotlarz
RESUMEN

Children with very early onset inflammatory bowel diseases (VEO-IBD) often have a refractory and severe disease course. A significant number of described VEO-IBD-causing monogenic disorders can be attributed to defects in immune-related genes. The diagnosis of the underlying primary immunodeficiency (PID) often has critical implications for the treatment of patients with IBD-like phenotypes. To identify the molecular etiology in 5 patients from 3 unrelated kindred with IBD-like symptoms, we conducted whole exome sequencing. Immune workup confirmed an underlying PID. Whole exome sequencing revealed 3 novel CARMIL2 loss-of-function mutations in our patients. Immunophenotyping of peripheral blood mononuclear cells showed reduction of regulatory and effector memory T cells and impaired B cell class switching. The T cell proliferation and activation assays confirmed defective responses to CD28 costimulation, consistent with CARMIL2 deficiency. Our study highlights that human CARMIL2 deficiency can manifest with IBD-like symptoms. This example illustrates that early diagnosis of underlying PID is crucial for the treatment and prognosis of children with VEO-IBD.